Pharsight

Jdp patents expiration

1. Quzyttir patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180090 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(6 years from now)

US8513259 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(6 years from now)

US9119771 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(6 years from now)

US8314083 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(6 years from now)

US8263581 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 4, 2022

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 October, 2019

Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

QUZYTTIR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic